1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Crestor remains the only branded statin in the 7MM covered in this forecast. It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin, which can boast a low cost and a preponderance of clinical trial data in support of its efficacy and safety. Nevertheless, when Crestor’s patent expires in the US in 2016 and in the EU and Japan in 2017, the use of rosuvastatin is likely to increase, but the gain in sales is likely to be allocated to the new generic options.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 18
3.1.3 Prognosis 19
3.1.4 Quality of Life 20
3.2 Symptoms 20
4 Disease Management 22
4.1 Treatment Overview 22
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Crestor (rosuvastatin) 34
6.1 Overview 34
6.2 Efficacy 36
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 38
7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 45
7.3 Methodology 49
7.4 Forecasting Methodology 49
7.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 49
7.4.2 Diagnosed Acute Coronary Syndrome Patients 50
7.4.3 Percent Drug-Treated Patients 51
7.4.4 General Pricing Assumptions 51
7.4.5 Individual Drug Assumptions 53
7.4.6 Generic Erosion 53
7.5 Physicians and Specialists Included in this Study 54
7.6 About the Authors 57
7.6.1 Author 57
7.6.2 Reviewer 57
7.6.3 Global Head of Healthcare 58
7.7 About GlobalData 59
7.8 Disclaimer 59

1.1 List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 16
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 16
Table 3: Symptoms of Acute Coronary Syndrome 21
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 25
Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014 27
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 33
Table 7: Product Profile - Crestor (rosuvastatin) 35
Table 8: Crestor (rosuvastatin) SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Crestor, 2013-2023 38
Table 10: Price Sources and Calculations, by Country 52
Table 11: Physicians Surveyed, By Country 56

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 14
Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome 15
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 17
Figure 4: Electrocardiography in the Diagnosis of ACS 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Simvastatin Global Market Report

2016 Simvastatin Global Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Simvastatin Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Simvastatin industry with a focus on the Chinese ...

2016 Lovastatin Global Market Report

2016 Lovastatin Global Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Lovastatin Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Lovastatin industry with a focus on the Chinese market. ...

Global and Chinese Lovastatin  Industry, 2016 Market Research Report

Global and Chinese Lovastatin  Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • October 2016
  • by Prof Research

The 'Global and Chinese Lovastatin  Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Lovastatin  industry with a focus on the Chinese ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Therapy Market and Diabetes Statistics in the UK

  • November 2016
    9 pages
  • Therapy  

    Statins  

    Diabetes  

  • United Kingdom  

View report >

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Related Market Segments :

Statins

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.